# A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue

> **NCT07248020** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Rectal Cancer
- Locally Advanced Rectal Cancer
- Radiation-Induced Enteritis
- Radiation Proctitis
- Chemoradiotherapy-Related Toxicity

## Interventions

- **DIETARY_SUPPLEMENT:** Curcumin (BCM-95®)

## Key facts

- **NCT ID:** NCT07248020
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07248020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07248020, "A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07248020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*